BPS Oncology Pharmacy Exam Questions

Pass Your BPS Oncology Pharmacy Exam On The First Attempt

By Dumpsbook BPS Oncology Pharmacy Exam Questions

BPS Oncology Pharmacy The BPS Board Certified Oncology Pharmacist (BCOP) program is a credential for pharmacists who have met the eligibility criteria below and who in their unique practice, involving an increasing number and complexity of drug therapies for treating and preventing cancer, manage cancer-related and drug-related adverse events or clinical situations not encountered in other disease states.

The purpose of the BCOP program is to validate that the pharmacist has the advanced knowledge and experience to optimize outcomes for patients with malignant diseases by: • Recommending, designing, implementing, monitoring, and modifying pharmacotherapeutic plans. • Reducing medication errors. • Recognizing and responding to adverse physical and emotional issues that may arise during treatment and when providing education and counseling. https://www.dumpsbook.com/Exam/BPS-ON

Question: 1 A 3-year-old girl diagnosed with ALL developed an urticarial rash on her upper body extremities and experienced mild bronchospasm 30 minutes into the infusion of her day-15 pegaspargase. The infusion was discontinued, and supportive care measures were instituted. Today is day 43, and the patient is due for her next scheduled dose of pegaspargase.

Which is the most appropriate course of action in this situation?

A. Substitute six doses of asparaginase Erwinia chrysanthemi for the one dose of pegaspargase.

B. Substitute nine doses of asparaginase Erwinia chrysanthemi for the one dose of pegaspargase.

C. Resume therapy with pegaspargase, but premedicate the dose with acetaminophen, diphenhydramine, and a corticosteroid.

D. Discontinue all further treatment with any form of asparaginase therapy.

Answers: A

https://www.dumpsbook.com/Exam/BPS-ON

Question: 2 According to USP General Chapter 797 rules, which of the following primary engineering controls cannot be used to compound sterile hazardous preparations?

A. B. C. D.

Class biological safety cabinet Class II, type B1 biological safety cabinet Class II, type B2 biological safety cabinet Class III biological safety cabinet

Answers: D

https://www.dumpsbook.com/Exam/BPS-ON

Question: 3 An institution is conducting a phase industry-sponsored trial for a new agent that is given for 21 days of a 28-day cycle to cohorts of three patients. A third patient has just been enrolled at the second dose level specified in the protocol. Dose-limiting toxicity (DLT) for this trial is defined as the dose that produces grade III or IV no hematologic toxicity during the first course of the agent. A new patient eligible for this trial presents to the clinic. Which of the following is the most appropriate procedure regarding enrollment of this new patient?

A. The new patient must wait until the three patients at the present dose level have completed their first full course of therapy so they can be observed for DLT. if no DLT is observed, the new patient can be enrolled at the next dose level.

B. The new patient should be enrolled at the next dose level because the protocol specifies that three patients should be enrolled at each dose level. After completion of the trial, a retrospective review of toxicity experienced at each dose level will determine the maximum tolerated dose.

C. The new patient should be enrolled at the present dose level immediately, and the dose should be adjusted for the second course on the basis of whether or not any of the first three patients experience any DLT during their first course of therapy.

D. The new patient must wait until the three patients at the present dose level have completed their first full course of therapy so they can be observed for DLT. If two of the three have a DLT, the patient should be enrolled at the same dose level along with two other new patients.

Answer: A

https://www.dumpsbook.com/Exam/BPS-ON

Question: 1 A 26-year-old female recently had a surgical resection of a cutaneous melanoma on her back. The melanoma had a Breslow depth of 5 mm without lymph node involvement (stage IIB). The patient is now being treated with adjuvant interferon alfa.

The recommended total duration of interferon therapy is: A. B. C. D.

6 months.

9 months.

12 months.

15 months.

Answer: C

https://www.dumpsbook.com/Exam/BPS-ON

Question: 5 A 4-year-old patient diagnosed with medulloblastoma has had a successful resection of the tumor with only minimal residual disease around the margins. The patient is now beginning alternating courses of cisplatin with etoposide and cyclophosphamide with vincristine. Which of the following complications requires close monitoring with each course of cyclophosphamide and vincristine?

A. B. C. D.

Tumor lysis syndrome Cushing syndrome Syndrome of inappropriate antidiuretic hormone Superior vena cava syndrome

Answer: C

https://www.dumpsbook.com/Exam/BPS-ON

Why Choose us to prepare and pass the BPS Oncology ❖3 Months Free Updates ❖BPS Oncology Pharmacy Exam Questions ❖Security and Privacy ❖Expert Quality BPS Oncology Pharmacy Exam Questions

https://www.dumpsbook.com/Exam/BPS-ON

Discount Get Special Discount by Using this Coupon Code “OFF20”

Visit Us @https://www.dumpsbook.com/Exam/BPS-ON